

# Index

## A

- Ablative lobar doses, 224
- Ablative therapies, 177, 186
  - bland embolization, 220–222
  - cryotherapy, 216–218
  - drug-eluting bead chemoembolization, 220
  - hybrid therapy, 226
  - IRE, 218–219
  - laser-induced thermotherapy, 219
  - microwave ablation, 216
  - PEI, 214–215
  - radioembolization, 222–226
  - RFA, 215–216
  - transarterial chemoembolization, 219–220
- Activated hepatic stellate cells, 180
- AFB1, *see* Aflatoxin B1
- Aflatoxin B1 (AFB1), 5–6, 69, 198
- AFLD, *see* Alcoholic fatty liver disease
- AFP, *see* Alpha-fetoprotein
- Alcohol, 5
- Alcohol-associated hepatocellular carcinoma, 79–82
- Alcoholic fatty liver disease (AFLD), 50
- Alcohol-related tumors, 239
- Alpha-fetoprotein (AFP), 51, 100, 182–183, 207, 214
- Angiogenesis, 243
- Anthracycline doxorubicin, 236
- Anticancer vaccination
  - DC-based vaccine, 187
  - DNA-based vaccine, 187–188
  - oncolytic virus therapy, 188
  - peptide-based vaccine, 187
  - tumor-specific immune response, 186
- Anti-CTLA-4 antibody, 186
- Anti-EGFR agents, 252
- Anti-FGF agents, 247–249, 252
- Anti-PD-1 antibody, HCC, 185–186
- Anti-PDGF agents, 246
- Antiproliferative/cell cycle, 253–254
- Antitumor immune response
  - suppression, 157–158
- $\alpha$ 1-Antitrypsin, 21, 24
- Anti-VEGF agents, 247–251
  - axitinib, 246
  - bevacizumab, 245–246
  - brivanib, 246
  - lenvatinib, 246
  - ramucirumab, 246
  - regorafenib, 245
  - sorafenib, 243–245
  - sunitinib, 245
- Arginase-1, 24
- Aspergillus* species, 36
- AT-rich interactive domain (ARID)1A, 197
- AXIN1* and *AXIN2* gene, 36–37
- Axitinib, 246

## B

- Barcelona Clinic Liver Cancer (BCLC)
  - classification, 50, 213, 224
- Basic helix-loop-helix (bHLH)
  - transcription factor, 135
- $\beta$ -Catenin pathway, 8–9, 34–35
- Bevacizumab, 245–246
- Bile pigment, 18
- Bland embolization, 220–222
- Bland portal vein embolization, 221
- Brightness mode (B-mode) ultrasound, 117
- Brivanib, 246

**C**

- Canalicular multispecific organic anion transporter (cMOAT), 123
- Cancer biomarkers
  - big data, 105
  - definition, 95–96
  - diagnosis, prognosis, and treatment, 102
    - liquid biopsy, 103–105
    - serum proteins, 102–103
  - discovery and validation, epidemiological considerations, 96–97
  - FDA-defined companion diagnostics and complementary diagnostics, 98–99
  - liver cancer
    - AFP, 100
    - AFP-L3, 100–101
    - DCP, 101
    - for post-resection surveillance, 102
    - predicting treatment responses, 101
  - meta-analyses and systematic reviews, 105
  - molecular diagnostic, 95
  - precision medicine, 95, 106
  - research efforts, 105–106
  - technology diffusion, 105
- Cancer metastasis, EMT and, 140
  - cancer cells
    - extravasation of, 142
    - intravasation, 141
  - malignant cell conversion and localized invasion, 141
  - secondary sites, cancer cell colonization, 142
  - systemic transport, 141–142
- Cancer stem cells (CSCs)
  - functional plasticity, 163
  - functional properties, 162–163
  - immune surveillance, 163
  - markers expression in CTCs, 161–162
  - mechanistic role, 162
  - molecular expressing patterns, 162–163
  - origin of, 162–163
  - primary tumors, 163
  - tumor self-seeding, 162
- Cancer vaccine
  - DC-based vaccine, 187
  - DNA-based vaccine, 187–188
  - oncolytic virus therapy, 188
  - peptide-based vaccine, 187
  - tumor-specific immune response, 186
- Capsule formation, 121
- Carcinoembryonic antigen (CEA), 214
- CD3<sup>+</sup> T cells, 157–158
- CD10, 18
- CD34, 18, 207
- CD45, 160
- CD81, 76
- CDK, *see* Cyclin-dependent kinases
- CEA, *see* Carcinoembryonic antigen
- Cell membranes, 18
- Cellular mutations, 243
- CEUS, *see* Contrast-enhanced ultrasound
- cfDNA, *see* Circulating cell-free DNA
- Chemotherapy-refractory tumor, 236
- Child-Pugh Class A cirrhosis, 243–244
- Child-Pugh score, cirrhosis mortality, 157
- Chromatin modification, 72
- Chromatin-remodeling gene mutations, 239
- Chromosome instability, 40
- Chronic liver disease, 56, 59
- Circulating cell-free DNA (cfDNA), 103–104
- Circulating tumor cells (CTCs), 104, 141–142
  - biology, 161
  - and cancer stem cells, 161–163
  - CD45, 160
  - circulatory shear stress, 160
  - diagnostic and prognostic measures, 161
  - epithelial cancers, 159
  - epithelial marker expression, 160
  - epithelial-to-mesenchymal transition, 161, 163–165
  - extracellular epithelial cell adhesion molecule, 160
  - limited half-life, 160
  - matrix-derived survival signals, 160
  - molecular analysis, 160
  - molecular linkage, 161
  - peripheral circulation, 159
  - pulmonary capillary beds, 160
  - pulmonary microvasculature, 160
- Circulating tumor stem cells (CTSCs), 163
- Cirrhosis
  - alcoholism, 154
  - etiology, 154
  - HBV/HCV infection, 154
  - metabolic disorders, 154
- CLAUDIN (CLDN), 76
- c-mesenchymal-epithelial transition factor-1 (c-MET) pathway, 243
- cMOAT, *see* Canalicular multispecific organic anion transporter
- CNAs, *see* Copy number alterations
- Cochrane Database review for cryoablation, 218
- Collagenous stroma, 21
- Combination chemotherapy, 237
- Combined hepatocellular-cholangiocarcinomas (HCC-CC), 28–30
- Computed tomography (CT), 118–121
- Contrast-enhanced ultrasound (CEUS), 118
- Conventional TACE (cTACE) technique, 220
- Copy number alterations (CNAs), 239, 240
- Core proteins, 3

CpG islands (CGIs), 70  
 CpG sites, 70–71  
 Cryotherapy, 216, 218  
 CSCs, *see* Cancer stem cells  
 CTCs, *see* Circulating tumor cells  
*CTNNB1* mutations, 35, 42  
 Cyclin-dependent kinase (CDK), 243, 253  
 Cyclin-dependent kinase inhibitor 2A (CDKN2A), 36  
 Cytokeratins 7 and 19, 205  
 Cytokines  
   inflammatory, 139  
   pro-inflammatory, 4  
   Th2, 156  
 Cytokine transforming growth factor  $\beta$  (TGF $\beta$ ), 37–38  
 Cytotoxic chemotherapy, 235–237  
 Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) blockade, 186

## D

DC-based vaccine, 187  
 DEB-TACE, *see* Drug-eluting bead TACE  
 DECT, *see* Dual-energy CT  
 Delayed phases, 120  
 Dendritic cells (DC), 180–181  
 Dendritic cells-based vaccine, 187  
 Des- $\gamma$ -carboxy prothrombin (DCP), 101  
 Diabetes, 50  
 Diethyl-nitrosamine (DEN), 82  
 Diffuse cirrhosis-like HCC (CL-HCC), 28  
 Diffusion-weighted imaging (DWI), 124–125  
 DNA-based vaccine, 187–188  
 DNA damage repair, 236  
 DNA methylation, 7, 70–71  
 DNA methyltransferase (DNMT), 76–77  
 DNA methyltransferase 1 (DNMT1), 73–74  
 DNA methyltransferase 3a (DNMT3a), 74  
 DNA mutations and genomic instability, 238  
 DNMT, *see* DNA methyltransferase  
 Doppler ultrasound, 117–118  
 Drug-eluting bead TACE (DEB-TACE), 220  
 Drug transporter proteins, 236  
 Dual-energy CT (DECT), 126–127  
 Dysplastic foci, 199–201  
 Dysplastic nodules, 201–203

## E

Early hepatocellular carcinoma, 204–205  
 E-cadherin, 7, 134, 135, 137, 139  
 EGF, *see* Epidermal growth factor  
 Elastography, 125–126

EMT, *see* Epithelial-to-mesenchymal transition  
 EMT-MET transition processes, 163  
 Enhanced cellular efflux mechanisms, 236  
 Epidermal growth factor (EGF), 235–236  
 Epigenetics  
   DNA methylation, 70–71  
   histone modifications and histone variants, 71–72  
   micro RNAs, 71  
 Epithelial cell adhesion molecule (EpcAM), 28, 38, 51, 61–62  
 Epithelial cells, 132–133  
 Epithelial-to-mesenchymal transition (EMT), 132–133, 161, 163–165, 236  
   biomarkers, 143  
   and cancer metastasis, 140  
   cancer cells, extravasation of, 142  
   cancer cells, intravasation, 141  
   malignant cell conversion and localized invasion, 141  
   secondary sites, cancer cell colonization, 142  
   systemic transport, 141–142  
 classification, 133  
 complex orchestration, 133  
   additional signaling pathways, 137–138  
   core regulators, 134–135  
   effectors, 134  
   hypoxia, 138  
   inflammatory cytokines, 139  
   MicroRNAs, 139  
   signaling pathways, 135, 136  
   TGF $\beta$ , 137  
 CSC phenotypes, 165  
 phenotypes, expression, 164  
 signal transduction, 164  
 therapeutic strategy, 143  
   effectors, 144  
   inducers, 144–145  
   transcription factors, 144  
 Epstein-Barr virus (EBV), 27  
 ErbB receptor family, 8  
 Erlotinib, 8, 252  
 European Association for the Study of the Liver (EASL), 213  
 Exosomes, 104–105

## F

FGF, *see* Fibroblast growth factor  
 FHCC, *see* Fibrolamellar HCC  
 Fibroblast growth factor (FGF), 235–236  
 Fibrolamellar hepatocellular carcinoma (FHCC), 21–24

- Fibrosis, 5  
 Fibrotic contraction, 225  
 Fluorescence resonance energy transfer (FRET), 55  
 Fms-like tyrosine receptor kinases (FLT3), 245  
 Focal adhesion kinase (FAK)-phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway, 156  
 Focal adhesion kinase (FAK) signaling, 155  
 Future liver remnant (FLR), 221
- G**
- Gadolinium chelates, 122  
 Gadoxetate disodium, 122–123  
 Gefitinib, 8  
 Gemcitabine, 237  
 Genetic alteration, 59–60, 62–63  
 Genetic mutations and drivers, 239–240  
 Glutamine synthetase (GS), 206  
 Glutathione (GSH), 79  
 Glypican 3 (GPC3), 18, 24, 183, 205–206  
 Golgi protein 73 (GP73), 103  
 GPC3, *see* Glypican 3 (GPC3)  
 G1/S cell cycle transition, 243  
 GS-FLX Titanium Systems, 53  
 GS Junior Systems, 53  
 Gypican 3 (GPC-3), 102–103
- H**
- HBV, *see* Hepatitis B virus  
 HCA519, 184  
 HCC, *see* Hepatocellular carcinoma  
 HCC-CC, *see* Hepatocellular carcinoma-cholangiocarcinomas  
 HCV, *see* Hepatitis C virus  
 HDACs, *see* Histone deacetylases  
 Heat shock protein (HSP), 236, 243  
 Heat shock protein 70 (HSP70), 206  
 Hepadnaviruses, *see* Hepatitis B virus)  
 Hepatic cryoablation, 218  
 Hepatic nodules  
   less useful markers  
     alpha-fetoprotein, 207  
     CD34 and Ki-67, 207  
     p53, 207  
   moderate utility, stains  
     cytokeratins 7 and 19, 205  
     glypican 3, 205–206  
     GPC3, HSP70 and GS combination, 206  
     GS, 206  
     HSP70, 206  
   molecular analysis, 207  
 Hepatic progenitor cells (HPCs), 28  
 Hepatic stellate cells (HSC), 154–156, 180  
 Hepatic transarterial brachytherapy, 222  
 Hepatitis B, 116  
 Hepatitis B virus (HBV), 2–3, 49, 73–75  
 Hepatitis C virus (HCV), 3, 49, 75–79  
 Hepatocarcinogenesis, 196, 200  
 Hepatocellular carcinoma (HCC), 1, 17  
   alcohol-associated hepatocellular carcinoma, 79–82  
   alternative treatment options, 131–132  
   biomarkers, 84 (*see* Cancer biomarkers)  
   conventional, 17–20  
   EMT (*see* Epithelial-to-mesenchymal transition (EMT))  
   epigenetics (*see* Epigenetics)  
   etiology, 1, 2  
   factor, 69  
   grading, 30, 31  
   HBV, 73–75  
   HCV, 75–79  
   hepatic nodules (*see* Hepatic nodules)  
   heterogeneity  
     at biological level, 51–52  
     clinical presentation, 50–51  
     in etiology, 49–50  
   and heterogeneity, 49  
   histologic subtypes  
     CL-HCC, 28  
     FHCC, 21–24  
     HCC-CC, 28–30  
     LEL-HCC, 27  
     sarcomatoid, 27  
     ScHCC, 24–26  
     SHCC, 27  
     undifferentiated carcinoma, 28  
   imaging (*see* Imaging)  
   incidence, 33  
   mechanisms with etiology, 6  
   molecular alterations  
     *AXIN1* and *AXIN2* gene, 36–37  
     *CDKN2A*, 36  
     chromosome instability, 40  
     EpCAM, 38  
     epigenetic alterations, 39–40  
     *MET*, 37  
     p53, 35–36  
     PTEN, 39  
     *RAS* family, 37  
     *TERT*, 33–34  
     TGF $\beta$ , 37–38  
     VEGFA, 38  
     Wnt/ $\beta$ -catenin pathway, 34–35  
   molecular classification, 40–41  
     nonproliferation class, 42  
     proliferation class, 41–42

- molecular mechanisms, 7
    - B-catenin, 8–9
    - ErbB receptor family, 8
    - MET and HGF, 7–8
    - methylation, 7
    - p53 tumor suppression, 9
  - NAFLD cirrhosis-induced
    - hepatocarcinogenesis, 4–5
  - NAFLD-NASH-associated hepatocellular carcinoma, 82–84
  - NGS (*see* Next-generation sequencing system)
  - pathogenesis, 196
    - cirrhotic background, 196–197
    - non-cirrhotic background, 197–198
  - p53 mutation/inactivation, 6
  - screening, 115–116
  - small HCC, 21
  - staging, 31
  - toxin-mediated hepatocarcinogenesis, 5
    - afatoxin-B1 induced, 5–6
    - alcohol induced, 5
  - virus-induced hepatocarcinogenesis
    - HBV, 2–3
    - HCV, 3
  - Hepatocellular carcinoma-
    - cholangiocarcinomas (HCC-CC), 28–30
  - Hepatocellular carcinoma-specific
    - antigens, 182
  - Hepatocyte growth factor (HGF), 7–8, 243
  - Hepatocyte necrosis and regeneration, 238
  - HGF, *see* Hepatocyte growth factor
  - High-grade dysplastic nodules (H-DNs), 201–202
  - HiSeq, 53–54
  - Histone deacetylases (HDACs), 235–236, 239, 242, 254
  - Histone modifications, 71–72
  - Histone variants, 71–72
  - HSC, *see* Hepatic stellate cells
  - HSP, *see* Heat shock protein
  - Human telomerase reverse transcriptase (hTERT), 184
  - Hybrid therapy, 226
  - Hyper variable region (HVR1), 76
  - Hypoxia, 138
  - Hypoxia-inducible factor 1 alpha (HIF-1 $\alpha$ ), 236
- I**
- Illumina sequencing, 53–54
  - Imaging
    - altered hemodynamics, 116
    - CT, 118–121
    - DECT, 126–127
    - elastography, 125–126
    - MRI, 121–125
    - patient care, implications, 127–128
    - ultrasound, 117–118
    - ultrasound surveillance algorithm, 118
  - Immune checkpoint inhibitors, 254–255
    - CTLA-4, 186
    - PD-L1, 185–186
  - Immune systems
    - adaptive, 181
    - detrimental effects, 177
    - innate, 181
  - Immune tolerance
    - innate and adaptive, 177–178
    - portal circulation, 178
  - Immunohistochemistry
    - GPC-3, 102
    - hepatic nodules
      - alpha-fetoprotein, 207
      - CD34 and Ki-67, 207
      - cytokeratins 7 and 19, 205
      - glypican 3, 205–206
      - GPC3, HSP70 and GS combination, 206
      - GS, 206
      - HSP70, 206
      - molecular analysis, 207
      - p53, 207
      - semiquantitative detection, 72
  - Immunomodulators, 254–255
  - Immunostaining, 72
  - Immunosuppressive mechanisms, 177–179
  - Immunotherapy
    - AFP, 182–183
    - clinical trials, 188
    - CTLA-4 blockade, 186
    - GPC3, 183
    - HCA519, 184
    - MAGE-A, 184
    - NY-ESO-1, 183–184
    - SSX-2, 184
    - TERT, 184
  - Inflammatory cytokines, 139
  - Integrins, 156
  - Interferon alpha (IFN $\alpha$ ) therapy, 51
  - Internal ribosomal entry site (IRES), 76
  - Ion Personal Genome Machine, 54–55
  - Irreversible electroporation (IRE), 218–219
- J**
- JAK/STAT pathway, 242
  - Joule-Thomson effect, 218

**K**

Ki-67, 207  
Kupffer cells, 180

**L**

Large cell change (LCC), 199–201  
Laser-induced thermotherapy (LITT), 219  
LCC, *see* Large cell change  
L-DNs, *see* Low-grade dysplastic nodules  
*Leus culinaris agglutinin*-reactive glycoform of AFP (AFP-L3), 100–101  
Lenvatinib, 246  
Light-activated drug therapy, 228  
Linifanib inhibitor, 246  
Liquid biopsy, 103–105  
Liver cancer biomarkers  
  AFP, 100  
  AFP-L3, 100–101  
  DCP, 101  
  for post-resection surveillance, 102  
  predicting treatment responses, 101  
Liver cell dysplasia (LCD), 196  
  biopsy diagnosis, 207–208  
  histologic classifications, 198–199  
  dysplastic foci, 199–201  
  dysplastic nodules, 201–203  
  early HCC, 204–205  
  progressed HCC, 205  
  small HCC, 204  
Liver diseases, benign, 160  
Liver Imaging Reporting and Data System (LI-RADS), 127–128  
Liver sinusoidal endothelial cells (LSEC), 179–180  
Liver's natural tolerogenicity, 177  
Liver transplantation, 159  
Local ablative therapies  
  bland embolization, 220–222  
  cryotherapy, 216–218  
  drug-eluting bead chemoembolization, 220  
  hybrid therapy, 226  
  IRE, 218–219  
  laser-induced thermotherapy, 219  
  microwave ablation, 216  
  PEI, 214–215  
  radioembolization, 222–226  
  RFA, 215–216  
  transarterial chemoembolization, 219–220  
Locoregional therapy (LRT)  
  bland embolization, 220–222  
  cryotherapy, 216–218  
  diagnosis, 214  
  disease stage, 214  
  drug-eluting bead chemoembolization, 220

  high-intensity focused ultrasound, 228  
  hybrid therapy, 226  
  imaging modalities, 214  
  IRE, 218–219  
  laser-induced thermotherapy, 219  
  microwave ablation, 216  
  patient evaluation, 214  
  PEI, 214–215  
  physiologic/immune potentiation, 228  
  physiologic/technical deficiencies, 214  
  radioembolization, 222–226  
  RFA, 215–216  
  in situ tumor destruction, 213–214  
  transarterial chemoembolization, 219–220  
  treatment evaluation, 226–228  
Low-grade dysplastic nodules (L-DNs), 201–202

LRT, *see* Locoregional therapy  
LSEC, *see* Liver sinusoidal endothelial cells  
Lymphoepithelioma-like HCC (LEL-HCC), 27

**M**

Magnetic resonance imaging (MRI)  
  DWI, 124–125  
  gadolinium chelates, 122  
  gadoxetate disodium, 122–123  
  in-phase and out-of-phase imaging, 124  
  many meta-analyses, 121  
  SPIO particles, 123  
Mammalian target of rapamycin (mTOR), 235–236  
Medical therapy for HCC, 176–177  
Melanoma antigen gene-A (MAGE-A), 184  
Membranous web, 76  
Mesenchymal stem cells (MSCs), 156  
Mesenchymal-to-epithelial transition (MET), 133, 163, 252–253  
Metastasis  
  biological properties, 153  
  colonization, 153  
  curative resection and resistance, 153  
  extravasation, 153  
  gene expression profiling, 154  
  hepatic microenvironment, 153  
  immune components  
    CD3<sup>+</sup> T cells, 157–158  
    TAMs, 158–159  
  inflammatory components  
    HSC, 154–156  
    MSCs, 156  
    TAFs, 156–157  
  initiation, 153  
  intravasation, 153

- tumor cell circulation (*see* Circulating tumor cells (CTCs))
- Methylation, 7, 77
- MET* proto-oncogene, 37
- MET receptor, 7–8
- Micro RNAs (miRs), 71, 83, 139
- miR-96, 75
  - miR-122, 78
  - miR-145, 75
  - miR-196b, 78
  - miR-199, 75
  - miR-602, 74–75
  - miR-718, 105
- Microwave ablation (MWA), 216, 217
- MinION system, 55
- MiSeq, 53
- MiSeqDx, 53
- Mitogen-activated protein kinase (MAPK) pathway, 60
- Molecular pathogenesis
- etiologies, 237
  - genetic mutations and drivers, 239–240
  - genomic alterations, 238
  - genomic heterogeneity, 238
  - mechanisms, 238
  - molecular themes and pathways, 239
  - signaling pathways, 240–243
  - telomerase reactivation, 238
  - telomere shortening, 238
- Molecular-targeted cancer therapies, 63–64
- anti-EGFR agents, 252
  - anti-FGF agents, 249–252
  - anti-PDGF agents, 246–249
  - anti-VEGF agents, 243–246
  - drugs, development, 252–255
- Monotherapy
- anthracycline doxorubicin, 236–237
  - capecitabine, 236–237
  - epirubicin, 236–237
  - 5-FU monotherapy, 237
  - gemcitabine, 236–237
  - hepatic dysfunction, 237
  - irinotecan, 236–237
  - mitoxantrone, 236–237
  - pegylated liposomal doxorubicin, 236–237
  - thalidomide, 236–237
- MRI, *see* Magnetic resonance imaging
- mTOR, *see* Mammalian target of rapamycin
- Myeloid-derived suppressor cells (MDSC), 180
- N**
- NAFLD, *see* Nonalcoholic fatty liver disease
- NAFLD cirrhosis-induced
- hepatocarcinogenesis, 4–5
  - NAFLD-NASH-associated hepatocellular carcinoma, 82–84
  - NASH, *see* Nonalcoholic steatohepatitis
  - National Cancer Care Network (NCCN), 96
  - N-cadherin, 134, 139, 144
  - Necroinflammation nonalcoholic steatohepatitis (NASH), 4
  - Negative predictive value (NPV), 96–97
  - Next-generation sequencing (NGS) system, 52
    - HCC genomics studies, 56
    - chromatin regulators, 60
    - epigenetic alterations in, 62–63
    - expression profiles, 61–62
    - PI3K/Akt/mTOR-pathway and MAPK pathway, 60
    - potential clinical utilization, 63
    - viral-related HCCs, risk factors in, 56–59
    - WNT/beta-catenin pathway and P53 pathway, 59–60  - Illumina sequencing, 53–54
  - Ion Personal Genome Machine, 54–55
  - Roche 454 sequencing, 52–53
  - SOLID sequencing, 54
  - third-generation sequencers, 55
- NK cell function, 181
- Non-AFLD (NAFLD), 50
- Nonalcoholic fatty liver disease (NAFLD), 1, 27, 69, 237
- Nonalcoholic steatohepatitis (NASH), 82–84
- Notch signaling pathway, 242
- NPV, *see* Negative predictive value
- Nucleosomes, 71
- NY-ESO-1, cancer testis antigen, 183–184
- O**
- Obesity, 50
  - OCCLUDIN (OCLN), 76
  - Oncogene amplifications, 239
  - Oncogenesis, 238
  - Oncolytic virus therapy, 188
  - Organic anion transporting polypeptide (OATP1), 123
  - Orthotopic xenograft mouse model, 155
  - Osteopontin (OPN), 103
  - Oxidative stress, 243
- P**
- Pale bodies, 21, 23
  - Palliative therapy, 177
  - Palliative whole-liver cytoreduction, 226
  - PDGF, *see* Platelet-derived growth factor
  - PDX model, tumor implantation, 84

- PEI, *see* Percutaneous ethanol injection
- Peptide-based vaccine, 187
- Percutaneous ethanol injection (PEI), 214–215
- Personal Genome Machine sequencing, 63
- p53, 35–36, 59–60, 207
- p53 tumor suppression, 9, 240–241
- Phosphatase and tensin homolog (PTEN), 39
- Phosphatidylinositol 3-kinase (PI3K), 60, 137, 241
- PI3K/mTOR inhibitors, 254
- Platelet-derived growth factor (PDGF), 6, 235–236
- Portal vein embolization (PVE), 221
- Portal vein invasion, 121
- Portal venous phase, 120
- Positive predictive value (PPV), 96–97
- Postoperative liver failure, 224, 225
- Programmed death-ligand-1 (PD-L1), 185–186
- Progressed hepatocellular carcinoma, 205
- Pro-inflammatory cytokines, 4
- Prothrombin induced by vitamin K absence (PIVKA) 2, 214
- Pseudoglandular appearance, 18
- PVE, *see* Portal vein embolization
- R**
- Radiation lobectomies, 224
- Radioembolization, 222–226
- Radiofrequency ablation (RFA), 215–216
- Ramucirumab, 246
- RAS family, 37
- RAS/MAPK pathway, 241–242, 253
- RASSF1A, 75
- Rearranged during transfection (RET), 245
- Receptor tyrosine kinases (RTKs), 137
- RECIST criteria, 255
- Regorafenib, 245
- Regulatory T cells (Tregs), 181–182
- RET, *see* Rearranged during transfection
- Reversible electroporation, 218
- RFA, *see* Radiofrequency ablation
- RNA deep sequencing, 61, 62
- Roche 454 sequencing, 52–53
- S**
- S-adenosylmethionine (SAM), 79
- Sarcomatoid hepatocellular carcinoma, 27
- Scavenger receptor B1 (SRB1), 76
- SCC, *see* Small cell change
- Scirrhous variant of HCC (ScHCC), 24–26
- Sensitivity, biomarker discovery, 96–97
- Serum proteins, 102–103
- Serum tumor markers, 214
- SHCC, *see* Steatohepatic hepatocellular carcinoma
- Shear wave elastography (SWE), 126
- Shotgun bisulfite sequencing, 62
- Signaling pathways, 240–243
- cyclin-dependent kinases, 243
- histone deacetylases, 242
- JAK/STAT pathway, 242
- Notch signaling, 242
- PI3K/AKT/mTOR pathway, 241
- p53 tumor suppressor, 240–241
- RAS/MAPK pathway, 241–242
- tumor suppressor retinoblastoma pathway, 243
- tyrosine kinase receptors, 243
- Wnt/ $\beta$ -catenin pathway, 241
- Single-molecule real-time (SMRT), 55
- Small cell change (SCC), 199–201
- Small hepatocellular carcinoma, 21, 204
- Small RNA deep sequencing, 58, 61, 62
- Snail transcription factors, 134–135
- SOLiD sequencing, 54
- Sonic hedgehog (SHH) ligand, 138
- Sorafenib, 51, 243–245
- Specificity, biomarker discovery, 96–97
- SPIO, *see* Superparamagnetic iron oxide
- SSX-2, 184
- Stains, 18
- Steatohepatic hepatocellular carcinoma (SHCC), 27
- Stellate cells, hepatic, 180
- Stereotactic body radiotherapy, 228
- STORM randomized controlled phase III trial, 255
- Stromal invasion, 202, 208
- Sunitinib, 245
- Superparamagnetic iron oxide (SPIO), 123
- T**
- TAAAs, *see* Tumor-associated antigens
- TACE, *see* Transarterial chemoembolization
- TAFs, *see* Tumor-associated fibroblasts
- TAMs, *see* Tumor-associated macrophages
- Telomerase reverse transcriptase (TERT), 33–34, 184, 196–197
- Telomere shortening, 196
- TERT, *see* Telomerase reverse transcriptase
- TGF- $\beta$ , *see* Transforming growth factor- $\beta$
- Th2 cytokines, 156



- Third-generation sequencers, 55  
TILs, *see* Tumor-infiltrating lymphocytes  
TNM staging systems, 213  
Toxin-mediated hepatocarcinogenesis, 5  
    aflatoxin-B1 induced, 5–6  
    alcohol induced, 5  
*TP53* mutations, 35–36, 236  
TPX2, 184  
Transarterial chemoembolization (TACE), 51, 219–220  
Transarterial embolization (TAE), 221  
Transforming growth factor- $\alpha$  (TGF $\alpha$ ), 8  
Transforming growth factor- $\beta$  (TGF- $\beta$ ), 78, 137, 155, 243, 253  
Transient elastography (TE), 126  
Transplantation, liver, 159  
Tumor-associated antigens (TAAs), 182  
    AFP, 182–183  
    GPC3, 183  
    HCA519, 184  
    MAGE-A, 184  
    NY-ESO-1, 183–184  
    SSX-2, 184  
    TERT, 184  
Tumor-associated fibroblasts (TAFs), 156–157  
Tumor-associated macrophages (TAMs), 139, 158–159  
Tumor cells  
    circulation (*see* Circulating tumor cells)  
    immune-mediated fibrosis, 214  
    necrosis, 214  
Tumor heterogeneity, 63  
Tumorigenesis, 154  
Tumor-infiltrating lymphocytes (TILs), 157, 184  
Tumor microenvironment  
    immune components  
        CD3<sup>+</sup> T cells, 157–158  
        TAMs, 158–159  
    inflammatory components  
        HSC, 154–156  
        MSCs, 156  
        TAFs, 156–157  
    initiation, 153  
    intravasation, 153  
Tumor proportion score (TPS), 99  
Tumor-related immune suppression, 178  
Tumor-specific immune response, 186  
Tumor-stroma interactions, 156, 157  
Tumor suppressor functions, 155  
Tumor suppressor retinoblastoma pathway, 243  
Tyrosine kinase receptors, 243
- U**  
Ultrasound, 117–118  
Ultrasound surveillance algorithm, 118  
Undifferentiated carcinoma, 28  
United Network for Organ Sharing and Organ Procurement and Transplant Network (UNOS-OPTN), 128
- V**  
Vaccination  
    anticancer  
        DC-based vaccine, 187  
        DNA-based vaccine, 187–188  
        oncolytic virus therapy, 188  
        peptide-based vaccine, 187  
        tumor-specific immune response, 186  
    cancer  
        DC-based vaccine, 187  
        DNA-based vaccine, 187–188  
        oncolytic virus therapy, 188  
        peptide-based vaccine, 187  
        tumor-specific immune response, 186  
Vaccinia virus-based immunotherapy, 228  
Vascular endothelial growth factor (VEGF), 6, 158, 235–236  
Vascular endothelial growth factor A (VEGFA), 38  
VEGF, *see* Vascular endothelial growth factor  
Virus-induced hepatocarcinogenesis  
    HBV, 2–3  
    HCV, 3
- W**  
Whole exome sequencing, 239  
Whole-genome bisulfite sequencing, 62  
Wnt/ $\beta$ -catenin pathway, 34–35, 241  
WNT/ $\beta$ -catenin pathway, 59–60
- Z**  
ZEB transcription factors, 135  
Zero-mode waveguide (ZMW), 55